Albumin-Based Nanoparticles for Drug Delivery
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (20 March 2023) | Viewed by 1912
Special Issue Editors
Interests: cellular therapy; nanomedicine; nanomaterials; theranostics; tumor; organ-on-chip; molecular imaging; medicine; cells; stroke; degenerative disease
Interests: Ionizing radiation; nanogel; biomaterial; nanotechnology
Special Issues, Collections and Topics in MDPI journals
Interests: gold nanoparticle; radiolytic synthesis; radiation technologies; gamma radiation; electron beam radiation; X-ray
Special Issue Information
Dear Colleagues,
Serum albumins, which are found in mammalian blood, bind to various ligands and transport them throughout the body. They also serve as a carrier for steroids, fatty acids, and thyroid hormones. Albumin is known to accumulate in malignant and inflamed tissue due to defective blood vessels combined with a defective lymphatic drainage system. Albumins are intrinsically less immunogenic, biocompatible, and biodegradable. They exhibit a lower cytotoxicity than other nanoparticles of proteins and polymers from natural or synthetic origin. Their charged moieties offer numerous possibilities for surface modification and interaction with various therapeutic molecules. Albumin can be considered an ideal delivery system designed by nature. Albumin nanoparticles, on the other hand, provide additional functionalities such as increased drug load, delivery tuning, improved stability and bioavailability of the system, modulation of active and passive targeting, and superior pharmacokinetic/pharmacodynamic profiles. This Special Issue will cover the following subjects:
- New synthetic routes based on sustainable and green nanotechnology;
- Covalent and non-covalent drug attachment;
- Drug load;
- Release profile, burst release;
- New applications of albumins and proteins nanoparticles;
- Stability and bioavailability;
- Applications in cancer therapy and diagnosis;
- Modulation of drug resistance;
- Modulation of circulation time;
- Toxicity, immunogenicity.
Dr. Ademar B. Lugão
Prof. Dr. Slawomir Kadlubowski
Dr. Lucas F. Freitas
Dr. Aryel Heitor Ferreira
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
